Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort

被引:227
作者
Armstrong, Matthew J. [1 ,2 ]
Houlihan, Diarmaid D. [2 ]
Bentham, Louise [3 ]
Shaw, Jean C.
Cramb, Robert [4 ]
Olliff, Simon [5 ]
Gill, Paramjit S. [3 ]
Neuberger, James M. [2 ]
Lilford, Richard J. [3 ]
Newsome, Philip N. [2 ]
机构
[1] Univ Birmingham, Liver Res Ctr, NIHR Biomed Res Unit, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England
[2] Queen Elizabeth Univ, Hosp Birmingham, Liver Unit, Birmingham, W Midlands, England
[3] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England
[4] Queen Elizabeth Hosp Birmingham, Dept Clin Biochem, Birmingham, W Midlands, England
[5] Queen Elizabeth Hosp Birmingham, Dept Radiol, Birmingham, W Midlands, England
基金
英国惠康基金;
关键词
Primary care; Non-alcoholic fatty liver; Fibrosis; Liver function test; TERM-FOLLOW-UP; SCORING SYSTEM; FUNCTION TESTS; RISK-FACTORS; PREVALENCE; FIBROSIS; POPULATION; NAFLD; VALIDATION; STEATOHEPATITIS;
D O I
10.1016/j.jhep.2011.03.020
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a common cause of abnormal LFTs in primary care, but there are no data defining its contribution nor reporting the range of NAFLD severity in this setting. This study seeks to calculate the range of disease severity of NAFLD in a primary care setting. Methods: Adult patients with incidental abnormal LFTs, in the absence of a previous history, or current symptoms/ signs of liver disease were prospectively recruited from eight primary care practices in Birmingham. NAFLD was diagnosed as fatty liver on ultrasound, negative serological liver aetiology screen, and alcohol consumption <= 30 and <= 20 g/day in males and females, respectively. The NAFLD Fibrosis Score (NFS) was calculated to determine the presence or absence of advanced liver fibrosis in subjects identified with NAFLD. Results: Data from 1118 adult patients were analysed. The cause of abnormal LFTs was identified in 55% (614/1118) of subjects, with NAFLD (26.4%; 295/1118) and alcohol excess (25.3%; 282/1118) accounting for the majority. A high NFS (>0.676) suggesting the presence of advanced liver fibrosis was found in 7.6% of NAFLD subjects, whereas 57.2% of NAFLD patients had a low NFS (<-1.455) allowing advanced fibrosis to be confidently excluded. Conclusions: NAFLD is the commonest cause of incidental LFT abnormalities in primary care (26.4%), of whom 7.6% have advanced fibrosis as calculated by the NFS. This study is the first of its kind to highlight the burden of NAFLD in primary care and provide data on disease severity in this setting. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:234 / 240
页数:7
相关论文
共 31 条
  • [11] Long-term follow-up of patients with NAFLD and elevated liver enzymes
    Ekstedt, Mattias
    Franzen, Lennart E.
    Mathiesen, Ulrik L.
    Thorelius, Lars
    Holmqvist, Marika
    Bodemar, Goran
    Kechagias, Stergios
    [J]. HEPATOLOGY, 2006, 44 (04) : 865 - 873
  • [12] The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years
    Feldstein, A. E.
    Charatcharoenwitthaya, P.
    Treeprasertsuk, S.
    Benson, J. T.
    Enders, F. B.
    Angulo, P.
    [J]. GUT, 2009, 58 (11) : 1538 - 1544
  • [13] HAMAGUCHI M, 2005, ANN INTERN MED
  • [14] Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease
    Harrison, S. A.
    Oliver, D.
    Arnold, H. L.
    Gogia, S.
    Neuschwander-Tetri, B. A.
    [J]. GUT, 2008, 57 (10) : 1441 - 1447
  • [15] LIVER INVESTIGATION IN 149 ASYMPTOMATIC PATIENTS WITH MODERATELY ELEVATED ACTIVITIES OF SERUM AMINOTRANSFERASES
    HULTCRANTZ, R
    GLAUMANN, H
    LINDBERG, G
    NILSSON, LH
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1986, 21 (01) : 109 - 113
  • [16] Design and validation of a histological scoring system for nonalcoholic fatty liver disease
    Kleiner, DE
    Brunt, EM
    Van Natta, M
    Behling, C
    Contos, MJ
    Cummings, OW
    Ferrell, LD
    Liu, YC
    Torbenson, MS
    Unalp-Arida, A
    Yeh, M
    McCullough, AJ
    Sanyal, AJ
    [J]. HEPATOLOGY, 2005, 41 (06) : 1313 - 1321
  • [17] Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
    Kotronen, Anna
    Peltonen, Markku
    Hakkarainen, Antti
    Sevastianova, Ksenia
    Bergholm, Robert
    Johansson, Lina M.
    Lundbom, Nina
    Rissanen, Aila
    Ridderstrale, Martin
    Groop, Leif
    Orho-Melander, Marju
    Yki-Jarvinen, Hannele
    [J]. GASTROENTEROLOGY, 2009, 137 (03) : 865 - 872
  • [18] Nonalcoholic fatty liver disease - A feature of the metabolic syndrome
    Marchesini, G
    Brizi, M
    Bianchi, G
    Tomassetti, S
    Bugianesi, E
    Lenzi, M
    McCullough, AJ
    Natale, S
    Forlani, G
    Melchionda, N
    [J]. DIABETES, 2001, 50 (08) : 1844 - 1850
  • [19] Health outcomes following liver function testing in primary care: a retrospective cohort study
    McLernon, David J.
    Donnan, Peter T.
    Ryder, Stephen
    Roderick, Paul
    Sullivan, Frank M.
    Rosenberg, William
    Dillon, John F.
    [J]. FAMILY PRACTICE, 2009, 26 (04) : 251 - 259
  • [20] Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
    McPherson, Stuart
    Stewart, Stephen F.
    Henderson, Elsbeth
    Burt, Alastair D.
    Day, Christopher P.
    [J]. GUT, 2010, 59 (09) : 1265 - 1269